Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

One of the classes of medications ­­– glucagon-like peptide-1 receptor agonists (GLP-1) – treats Type 2 diabetes by stimulating insulin release by the pancreas, delaying gastric emptying ...

As the FDA issues a new warning about aspiration across all GLP-1 weight loss drugs, doctor groups are giving new ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

You can’t go far lately without seeing news and social media coverage of GLP-1 (glucagon-like peptide-1) receptor agonists ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

Other GLP-1 drugs, such as exenatide (Byetta®) and liraglutide (Victoza®), have been linked with lean mass loss. Other diabetes drugs ... semaglutide topped a list of drug spending in the ...

opens new tab on Tuesday that most patients do not need to stop taking GLP-1 diabetes and weight-loss drugs before surgery, a ruling supported by a study presented this week at a medical meeting ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications ... Type 2 diabetes and types of cancer," the researchers noted ...